Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by newdaydawningon Nov 09, 2019 6:13pm
223 Views
Post# 30332033

TLT and Merck: A match made in heaven

TLT and Merck: A match made in heavenTLT will need a life-science heavyweight as a go-to-market partner, preferably through a licensing, royalty and milestone payment arrangement.

Without a doubt, the most obvious prospective partner is the German giant, Merck.

As the world's only supplier of BCG, Merck is already omnipresent in the NMIBC treatment business.

So why would Merck want to do a deal with TLT?

Largely because Merck is making little, if any money on BCG.

Now envision a scenario where Merck is fronting TLT's FDA-approved PDT for NMIBC.

And that's just the starting point. With Merck guiding commercialization, we would see a much faster route to EU approval.

But the best outcome of all is that Merck spearheads whatever trials are required for TLT's NMIBC to be declared STANDARD OF CARE.

So Merck retains its status as the leader in NMIBC, but now it has a treatment with plenty of profit potential.

But there's another important angle to this story that gives further credence to a possible TLT-Merck hook-up.

The TLD-1433 compound is produced by Sigma-Aldrich, acquired by Merck in a US$17M deal five years ago.

So TLT already has a foot in the door with a Merck unit. And that helps makes the case for a bigger partnership where two leaders in NMIBC join forces to bring the best and most patient-friendly treatment to those afflicted with bladder cancer.





Bullboard Posts